Literature DB >> 29807796

New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting.

R Rondanin1, G Lettini2, P Oliva1, R Baruchello1, C Costantini1, C Trapella1, D Simoni1, T Bernardi1, L Sisinni2, M Pietrafesa2, G Ponterini3, M P Costi3, T Vignudelli3, R Luciani3, D S Matassa4, F Esposito5, M Landriscina6.   

Abstract

TRAP1 (Hsp75) is the mitochondrial paralog of the Hsp90 molecular chaperone family. Due to structural similarity among Hsp90 chaperones, a potential strategy to induce apoptosis through mitochondrial TRAP1 ATPase inhibition has been envisaged and a series of compounds has been developed by binding the simple pharmacophoric core of known Hsp90 inhibitors with various appendages bearing a permanent cationic head, or a basic group highly ionizable at physiologic pH. Cationic appendages were selected as vehicles to deliver drugs to mitochondria. Indeed, masses of new derivatives were evidenced to accumulate in the mitochondrial fraction from colon carcinoma cells and a compound in the series, with a guanidine appendage, demonstrated good activity in inhibiting recombinant TRAP1 ATPase and cell growth and in inducing apoptotic cell death in colon carcinoma cells.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Anticancer activity; Apoptosis; Lipophilic cations; Mitochondrial targeting; TRAP1 inhibitors

Mesh:

Substances:

Year:  2018        PMID: 29807796     DOI: 10.1016/j.bmcl.2018.05.031

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

Review 1.  HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy.

Authors:  Valentina Condelli; Fabiana Crispo; Michele Pietrafesa; Giacomo Lettini; Danilo Swann Matassa; Franca Esposito; Matteo Landriscina; Francesca Maddalena
Journal:  Cells       Date:  2019-06-03       Impact factor: 6.600

2.  Development of a biosensor platform based on ITO sheets modified with 3-glycidoxypropyltrimethoxysilane for early detection of TRAP1.

Authors:  Berfin Vural; Meltem ÇaliŞkan; Mustafa Kemal SezgİntÜrk
Journal:  Turk J Chem       Date:  2020-04-01       Impact factor: 1.239

3.  Computational Approaches for the Design of Novel Anticancer Compounds Based on Pyrazolo[3,4-d]pyrimidine Derivatives as TRAP1 Inhibitor.

Authors:  Amena Ali; Magda H Abdellattif; Abuzer Ali; Ola AbuAli; Mohd Shahbaaz; Mohamed Jawed Ahsan; Mostafa A Hussien
Journal:  Molecules       Date:  2021-09-30       Impact factor: 4.411

Review 4.  Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins.

Authors:  Clélia Mathieu; Samir Messaoudi; Elias Fattal; Juliette Vergnaud-Gauduchon
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 5.  Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer.

Authors:  Rosario Avolio; Danilo Swann Matassa; Daniela Criscuolo; Matteo Landriscina; Franca Esposito
Journal:  Biomolecules       Date:  2020-01-14

6.  TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas.

Authors:  Francesca Maddalena; Valentina Condelli; Danilo Swann Matassa; Consiglia Pacelli; Rosella Scrima; Giacomo Lettini; Valeria Li Bergolis; Michele Pietrafesa; Fabiana Crispo; Annamaria Piscazzi; Giovanni Storto; Nazzareno Capitanio; Franca Esposito; Matteo Landriscina
Journal:  Mol Oncol       Date:  2020-10-30       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.